Antonio González Martín-rekin lankidetzan egindako argitalpenak (31)

2024

  1. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

    International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  3. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  4. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2021

  1. Giant port-site recurrence after laparoscopic-staging for endometrial cancer

    International Journal of Gynecological Cancer

2020

  1. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    International Journal of Gynecological Cancer

  2. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    Obstetrical and Gynecological Survey

2019

  1. Early-stage mucinous carcinoma (infiltrative type) of the ovary and fertility preservation

    International Journal of Gynecological Cancer, Vol. 29, Núm. 4, pp. 835-839

2018

  1. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

    Annals of Oncology

  2. Is there a role for HIPEC in ovarian cancer?

    Archives of Gynecology and Obstetrics

2017

  1. Advanced stage yolk sac ovarian tumour: Clinical approach with cytoreductive surgery upfront

    European Journal of Gynaecological Oncology, Vol. 38, Núm. 2, pp. 311-313

2016

  1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 27, Núm. 1, pp. 16-41

  2. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited

    Gynecologic Oncology, Vol. 142, Núm. 3, pp. 597-607

  3. Minimal Macroscopic Residual Disease (0.1-1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer?

    International Journal of Gynecological Cancer, Vol. 26, Núm. 5, pp. 906-911

  4. What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?

    Annals of Surgical Oncology, Vol. 23, Núm. 5, pp. 1666-1673

2015

  1. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer

    Gynecologic Oncology, Vol. 136, Núm. 1, pp. 130-135

  2. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. First-line and maintenance therapy for ovarian cancer: Current status and future directions

    Drugs, Vol. 74, Núm. 8, pp. 879-889

  2. Utilidad de la PET/TC en el manejo del cáncer de vulva

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 33, Núm. 2, pp. 87-92

2013

  1. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer

    Expert Review of Anticancer Therapy, Vol. 13, Núm. 2, pp. 123-129